Welcome to our dedicated page for Spero Therapeuti SEC filings (Ticker: SPRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the real story inside a biotech filing is challenging. Spero Therapeutics’ disclosures weave clinical acronyms, FDA milestones, and royalty math into hundreds of pages. Whether you need the next Spero Therapeutics annual report 10-K simplified or want Spero Therapeutics 8-K material events explained, the details that drive valuation hide in dense footnotes and trial tables.
Stock Titan’s AI-powered analysis turns that maze into clarity. Our platform delivers Spero Therapeutics SEC filings explained simply—from the latest Spero Therapeutics quarterly earnings report 10-Q filing to Spero Therapeutics proxy statement executive compensation. Interactive dashboards surface R&D spend, cash runway, and partnership revenue, while side-by-side comparisons track tebipenem HBr and SPR206 progress across quarters. Need trading intel? We stream Spero Therapeutics Form 4 insider transactions real-time so you never miss Spero Therapeutics executive stock transactions Form 4. Each document is paired with concise AI summaries, keyword search, and instant red-line changes—saving hours and reducing errors.
Analysts, portfolio managers, and life-science investors rely on these insights to:
- Monitor R&D milestones and burn rate without combing through every note
- Compare quarter-over-quarter pipeline updates using our Spero Therapeutics earnings report filing analysis
- Track Spero Therapeutics insider trading Form 4 transactions before catalyst events
- Quickly answer boardroom questions by understanding Spero Therapeutics SEC documents with AI
Anson-managed entities reported beneficial ownership of 1,615,469 shares of Spero Therapeutics common stock, representing 2.9% of the 55,910,641 shares outstanding. The holdings are disclosed on a Schedule 13G/A dated for the event 06/30/2025 and signed on 08/14/2025 by representatives of Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo and Moez Kassam.
The filing states the shares are held by the Fund and that the position is held in the ordinary course of business and not to influence control of the issuer. Voting and dispositive power over the 1,615,469 shares is shown as shared (no sole power reported). The filing cites the issuer's outstanding share count from the issuer's May 13, 2025 quarterly report.
Spero Therapeutics registered an additional 3,000,000 shares of common stock under its 2017 Stock Incentive Plan, as amended, representing an increase in shares reserved for employee awards. The registration statement incorporates by reference prior Form S-8 filings for the same plan and includes key exhibits such as the amended plan, forms of award agreements, counsel opinion and the independent auditor's consent.
Spero Therapeutics (SPRO) reported a strong clinical milestone and narrower losses in the quarter ended June 30, 2025. The pivotal Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint and was stopped early for efficacy after a pre-specified interim analysis of 1,690 patients, and the company has shifted its R&D focus to tebipenem while suspending SPR720 oral development and discontinuing SPR206.
Financially, total revenues were $14.2 million for the quarter and $20.1 million for the six months, driven by related-party collaboration revenue and grant revenue. Net loss improved to $1.7 million for the quarter ($0.03 per share) and $15.6 million for six months ($0.28 per share), compared with larger losses a year earlier. Cash and cash equivalents were $31.2 million at June 30, 2025, down from $52.9 million at year-end, and the company used $21.7 million of cash in operations in the six months. The company received significant upfront and milestone payments from GSK (including a $66.0 million upfront payment) and reports committed BARDA funding of $65.6 million (with $61.1 million recognized to date). The company disclosed an SEC Wells Notice and ongoing cooperation with the staff, and regained Nasdaq bid-price compliance on June 12, 2025.
Spero Therapeutics announced it issued a press release reporting results for the third quarter ended June 30, 2025. The 8-K furnishes that press release as Exhibit 99.1, but the filing itself does not include the underlying financial figures in-line.
The company also furnished an investor presentation as Exhibit 99.2, which management intends to use in investor communications and is available on the company website. Both the press release and presentation are described as "furnished" and are not deemed "filed" for purposes of certain securities-law liabilities.
Spero Therapeutics’ Form 8-K details the voting results of its 12 June 2025 Annual Meeting. A quorum of 40,015,633 shares (71.57%) of the 55.9 million shares outstanding was present.
Board elections: Class II directors Frank E. Thomas, Patrick Vink M.D., and Esther Rajavelu were re-elected through 2028, each receiving roughly 25.7 million votes for and 0.4-2.9 million votes withheld; 13.8 million broker non-votes were recorded.
Auditor ratification: PricewaterhouseCoopers LLP was confirmed as independent auditor for FY 2025 with an overwhelming 39.8 million ‘for’ versus 175 k ‘against’.
Say-on-pay: Executive compensation received shareholder support—25.18 million ‘for’ (96.0%) against 0.64 million ‘against’.
Equity plan amendment: Shareholders approved increasing the 2017 Stock Incentive Plan by 3 million additional shares (22.97 million for / 3.15 million against). This authorizes extra equity that may dilute existing holders once issued but expands flexibility to attract and retain talent.
No financial performance data, earnings guidance, or major strategic transactions were disclosed; the filing is limited to governance and compensation matters.
FAQ
What is the current stock price of Spero Therapeuti (SPRO)?
What is the market cap of Spero Therapeuti (SPRO)?
